Other studies have also shown that the rate of ARID1A mutation or loss of expression in human IPMN samples is substantially higher than in human PDAC samples [3,5,7,8]. This evidence concerns the gene ARID1A and pancreatic intraductal papillary-mucinous neoplasm.